We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Under the terms of the extension of the agreement, Sygnature and Cyprotex will expand their collaborative sales and marketing initiative to provide a fully-integrated discovery chemistry/ADME-Tox/DMPK service to accelerate their clients’ drug discovery projects into development.

Dr Anthony Baxter, Chief Executive Offer at Cyprotex said, "We are delighted to have extended our strategic alliance with Sygnature.  The quality of their work and their desire to help customers achieve scientific success has enabled both of us to form a formidable combined offering in medicinal chemistry-driven integrated drug discovery and ADME-Tox services.  Since we commenced this relationship there have been several changes to both companies.  Both Sygnature and Cyprotex have expanded considerably, with Cyprotex acquiring Apredica, a Boston based ADME-Tox specialist CRO and the assets of Cellumen Inc, through which Cyprotex can now offer proprietary high content toxicology assays under the Cellciphr® brand name.  Sygnature have grown organically over the past two years and recently announced the formation of a strategic alliance with Saretius Limited, a pre-clinical experimental services company offering ‘gold standard’ models in pain, CNS disorders, inflammatory and metabolic diseases.  Our experience with Sygnature over the past year has led us both to conclude that we can successfully deliver integrated drug discovery services to our customers, and we wish to strengthen this offering in the future.”

Commenting on the partnership Dr Simon Hirst, Sygnature’s CEO said, “We have found the strategic alliance with Cyprotex to be highly beneficial to our clients over the past two years.  Working with Cyprotex is a key component of our portfolio of pre-clinical services as we have grown and expanded to offer our clients integrated drug discovery services.  Cyprotex has an enviable reputation as a CRO which provides premium ADME-Tox/DMPK services, so I am delighted that we will continue working together for two more years to offer our clients an exceptional, fully-integrated drug discovery service.  At Sygnature, we strongly believe that modern drug discovery requires the marriage of medicinal chemistry, biology, in vitro ADME and disease-specific models.  Our team of over 50 medicinal chemists are experienced in using ADME data to drive programmes forward into proof-of-concept studies.  Over the past four years, Sygnature and Cyprotex have collaborated on a number of drug discovery programmes for clients.  We have a dedicated project manager at Cyprotex focused on our clients’ projects, and scientists from both organisations have established a very close working relationship.  I am confident that future customers will see the benefits of working with Sygnature, Cyprotex and Saretius, acknowledged centres of excellence in their particular fields, to accelerate their drug discovery programmes forward into development.”